Featuring a 45,000-sq-ft, two-level building expansion with a 10,000-sq-ft retrofit of existing space, this project more than doubles Rentschler Biopharma’s commercial cGMP biopharmaceutical manufacturing capacity aimed at treating multiple diseases, such as cancer and COVID-19.